Biocon Hopes For EU Insulin Launch In Two Years; Pushes On With A Maturing Pipeline
This article was originally published in PharmAsia News
Executive Summary
India’s Biocon moves forward with recombinant insulin in Europe while working on its own innovative biologics pipeline for emerging markets. With that dual strategy, Biocon expects big triggers for growth.